Nathaniel M. Rickles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nathaniel M. Rickles has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Ha Trinh
Microsoft Research, Redmond, WA, USA
2 shared publications - Jennifer L. Bacci
University of Washington School of Pharmacy, Seattle, WA
2 shared publications - Reza Asadi
Department of Environment, Bushehr Branch, Islamic Azad University, Bushehr, Iran
2 shared publications - Ricardo Cruz
General Internal Medicine, Boston Medical Center, Boston, MA, United States
2 shared publications - Stefan Olafsson
Reykjavik University
2 shared publications - Teresa K. O'LEary
Yale School of Public Health, Yale University, New Haven, Connecticut, USA and NYU Grossman School of Medicine, New York, New York, USA
2 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 67 (1) , 103537
Defining pharmacist's role in optimizing prescription digital therapeutics for patients with schizophrenia: A modified Delphi consensus perspective
- 1 October 2026
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 67 (1) , 103537
Open AccessDefining pharmacist's role in optimizing prescription digital therapeutics for patients with schizophrenia: A modified Delphi consensus perspective
- 2 April 2026
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 18 (7) , 102582
10th anniversary: The development, implementation, and evaluation of a novel peer-assisted learning (PAL) program
- 2 April 2026
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 18 (7) , 102582
10th anniversary: The development, implementation, and evaluation of a novel peer-assisted learning (PAL) program
- 16 July 2025
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 89 (9) , 101466
Building Implementation Science Capacity in Academic Pharmacy: Report of the 2020–2021 AACP Research and Graduate Affairs Committee
- 16 July 2025
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 89 (9) , 101466
Building Implementation Science Capacity in Academic Pharmacy: Report of the 2020–2021 AACP Research and Graduate Affairs Committee
- 15 October 2022
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 63 (2) , 491-499.e2
A narrative review: Pharmacy intervention fidelity
- 15 October 2022
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 63 (2) , 491-499.e2
A narrative review: Pharmacy intervention fidelity
- Open Access
- 30 June 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (6) , e0269809
The association of prescription opioid use with suicide attempts: An analysis of statewide medical claims data
Background: Suicides and opioid overdose deaths are among the most pressing public health concerns in the US. However direct evidence for the association between opioid use and suicidal behavior is limited. The objective of this article is to examine the association between frequency and dose of prescription opioid use and subsequent suicide attempts.Methods and findings: This retrospective cohort study analyzed 4 years of statewide medical claims data from the Connecticut All-Payer Claims Database. Commercially insured adult patients in Connecticut (n = 842,773) who had any medical claims beginning in January 2012 were followed through December 2015. The primary outcome was suicide attempt identified using International Classification of Diseases (ICD 9) diagnosis codes. Primary predictor variables included frequency of opioid use, which was defined as the number of months with claims for prescription opioids per year, and strength of opioid dose, which was standardized using morphine milligram equivalent (MME) units. We also controlled for psychiatric and medical comorbidities using ICD 9 codes. We used Cox proportional hazards regression to examine the association between frequency, dose, and suicide attempts, adjusting for medical and psychiatric comorbid conditions. Interactions among measures of opioid use and comorbid conditions were analyzed.In this cohort study with follow-up time up to 4 years (range = 2–48 months, median = 46 months), the hazard ratios (HR) from the time-to-event analysis indicated that patients prescribed opioid medications for at least 6 months during the past year and at 20–50 MME levels or higher had 4.44 (95% CI: [3.71, 5.32]) to 7.23 (95% CI: [6.22, 8.41]) times the risk of attempted suicide compared to those not prescribed opioids. Risk of suicide attempt was sharply elevated among patients with psychiatric conditions other than anxiety who were prescribed more frequent and higher opioid doses. In contrast, more frequent and higher doses of prescription opioids were associated with lower risk of suicide attempts among patients with medical conditions necessitating pain management.This study is limited by its exclusive focus on commercially insured patients and does not include patients covered by public insurance. It is also limited to patients’ receipt of prescription opioids and does not take into account opioids obtained through other means, nor does it include measures of actual patient opioid use.Conclusions: This analysis provides evidence of a complex relationship among prescription opioids, mental health, pain and other medical comorbidities, and suicide risk. Findings indicate the need for proactive suicide surveillance among individuals diagnosed with affective or psychotic disorders who are receiving frequent and high doses of opioids. However, appropriate opioid treatment may have significant value in reducing suicide risk for those without psychiatric comorbidities.
- 30 June 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (6) , e0269809
Open AccessThe association of prescription opioid use with suicide attempts: An analysis of statewide medical claims data
Background: Suicides and opioid overdose deaths are among the most pressing public health concerns in the US. However direct evidence for the association between opioid use and suicidal behavior is limited. The objective of this article is to examine the association between frequency and dose of prescription opioid use and subsequent suicide attempts.Methods and findings: This retrospective cohort study analyzed 4 years of statewide medical claims data from the Connecticut All-Payer Claims Database. Commercially insured adult patients in Connecticut (n = 842,773) who had any medical claims beginning in January 2012 were followed through December 2015. The primary outcome was suicide attempt identified using International Classification of Diseases (ICD 9) diagnosis codes. Primary predictor variables included frequency of opioid use, which was defined as the number of months with claims for prescription opioids per year, and strength of opioid dose, which was standardized using morphine milligram equivalent (MME) units. We also controlled for psychiatric and medical comorbidities using ICD 9 codes. We used Cox proportional hazards regression to examine the association between frequency, dose, and suicide attempts, adjusting for medical and psychiatric comorbid conditions. Interactions among measures of opioid use and comorbid conditions were analyzed.In this cohort study with follow-up time up to 4 years (range = 2–48 months, median = 46 months), the hazard ratios (HR) from the time-to-event analysis indicated that patients prescribed opioid medications for at least 6 months during the past year and at 20–50 MME levels or higher had 4.44 (95% CI: [3.71, 5.32]) to 7.23 (95% CI: [6.22, 8.41]) times the risk of attempted suicide compared to those not prescribed opioids. Risk of suicide attempt was sharply elevated among patients with psychiatric conditions other than anxiety who were prescribed more frequent and higher opioid doses. In contrast, more frequent and higher doses of prescription opioids were associated with lower risk of suicide attempts among patients with medical conditions necessitating pain management.This study is limited by its exclusive focus on commercially insured patients and does not include patients covered by public insurance. It is also limited to patients’ receipt of prescription opioids and does not take into account opioids obtained through other means, nor does it include measures of actual patient opioid use.Conclusions: This analysis provides evidence of a complex relationship among prescription opioids, mental health, pain and other medical comorbidities, and suicide risk. Findings indicate the need for proactive suicide surveillance among individuals diagnosed with affective or psychotic disorders who are receiving frequent and high doses of opioids. However, appropriate opioid treatment may have significant value in reducing suicide risk for those without psychiatric comorbidities.
- 1 July 2021
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 61 (4) , 408-417
The use of an integrated opioid and medical marijuana prescription drug monitoring program
- 1 July 2021
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 61 (4) , 408-417
The use of an integrated opioid and medical marijuana prescription drug monitoring program
- 2 September 2020
- Published by Springer Nature in The Journal of Behavioral Health Services & Research
- Vol. 48 (3) , 446-467
Use of the Jung/Myers Model of Personality Types to Identify and Engage with Individuals at Greatest Risk of Experiencing Depression and Anxiety
Depression is the leading cause of ill health and disability worldwide. Objectives were (1) to determine the strength of the association between personality type with depression and anxiety using the Preferred Communication Style Questionnaire (PCSQ©) and the Four-Item Patient Health Questionnaire for Depression and Anxiety (PHQ-4) and (2) evaluate the extent to which severity of depression and anxiety is associated with personality type. Data were collected via a self-administered online survey of 10,500. Chi-square analysis compared personality types and depression and anxiety. Practical significance was determined by calculating the percentage-from-expected score based on established statistics reflecting each personality type’s percentage in the US population. Personality type was strongly associated with both depression and anxiety with certain types at significantly greater risk than others. Findings can improve the research and clinical community’s understanding of the specific risk factors and triggers for depression and anxiety, and result in more efficacious, tailored treatment options.
- 2 September 2020
- Published by Springer Nature in The Journal of Behavioral Health Services & Research
- Vol. 48 (3) , 446-467
Use of the Jung/Myers Model of Personality Types to Identify and Engage with Individuals at Greatest Risk of Experiencing Depression and Anxiety
Depression is the leading cause of ill health and disability worldwide. Objectives were (1) to determine the strength of the association between personality type with depression and anxiety using the Preferred Communication Style Questionnaire (PCSQ©) and the Four-Item Patient Health Questionnaire for Depression and Anxiety (PHQ-4) and (2) evaluate the extent to which severity of depression and anxiety is associated with personality type. Data were collected via a self-administered online survey of 10,500. Chi-square analysis compared personality types and depression and anxiety. Practical significance was determined by calculating the percentage-from-expected score based on established statistics reflecting each personality type’s percentage in the US population. Personality type was strongly associated with both depression and anxiety with certain types at significantly greater risk than others. Findings can improve the research and clinical community’s understanding of the specific risk factors and triggers for depression and anxiety, and result in more efficacious, tailored treatment options.
- Open Access
Training Community Pharmacy Staff How to Help Manage Urgent Mental Health Crises
Nearly 44 million Americans are affected by mental illness every year. Many individuals, however, are not diagnosed and/or do not receive treatment. The present manuscript reviews the incidence of mental illness, the continuum from mental wellness to mental illness, and the role of the pharmacy staff in helping individuals manage different mental health needs. In particular, there is discussion of stigma of mental illness that those with mental health needs experience by those around them including health professionals such as pharmacy staff. One way to resolve such stigma is through training such as Mental Health First Aid (MHFA). The paper reviews key aspects of MHFA, the evidence supporting MHFA, and how MHFA relates specifically to pharmacy practice and services. A conceptual framework for MHFA and its relationship to individual factors, attitudes, behaviors, and outcomes. Lastly, a discussion is presented that briefly compares MHFA to other similar approaches to helping those in mental health crises, the limits of what is known about MHFA, and what future research might explore to better understand the outcomes of pharmacy staff providing mental health education, support, and referral to care.
Open AccessTraining Community Pharmacy Staff How to Help Manage Urgent Mental Health Crises
Nearly 44 million Americans are affected by mental illness every year. Many individuals, however, are not diagnosed and/or do not receive treatment. The present manuscript reviews the incidence of mental illness, the continuum from mental wellness to mental illness, and the role of the pharmacy staff in helping individuals manage different mental health needs. In particular, there is discussion of stigma of mental illness that those with mental health needs experience by those around them including health professionals such as pharmacy staff. One way to resolve such stigma is through training such as Mental Health First Aid (MHFA). The paper reviews key aspects of MHFA, the evidence supporting MHFA, and how MHFA relates specifically to pharmacy practice and services. A conceptual framework for MHFA and its relationship to individual factors, attitudes, behaviors, and outcomes. Lastly, a discussion is presented that briefly compares MHFA to other similar approaches to helping those in mental health crises, the limits of what is known about MHFA, and what future research might explore to better understand the outcomes of pharmacy staff providing mental health education, support, and referral to care.
- 19 August 2019
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 16 (6) , 766-775
Three opportunities for standardization: A literature review of the variation among pharmacists’ patient care services terminology
- 19 August 2019
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 16 (6) , 766-775
Three opportunities for standardization: A literature review of the variation among pharmacists’ patient care services terminology